Navigation Links
Monogram Presents Results of First ETag Breast Cancer Studies

Monogram Biosciences, Inc. announced that two presentations detailing initial studies on the clinical utility of its proprietary eTag technology in metastatic breast cancer will be presented at the 43rd American Society of Clinical Oncology (ASCO) meeting (June 1-5) in Chicago, Illinois. A third presentation will describe the molecular characterization of cell lines that have acquired resistance to the breast cancer drug Herceptin (trastuzumab).

Currently under development, the eTag technology is a highly advanced diagnostic platform for quantifying protein expression, protein-protein interactions (e.g. receptor dimerization) and protein modification (e.g. phosphorylation). This unique capability enables the eTag technology to accurately assess signaling pathways that control cell growth, proliferation and survival. Dysregulation of these pathways has been associated with a wide variety of tumors, including breast, lung, prostate and colorectal cancers.

Many new therapeutic candidates target various steps in these critical cell signaling pathways, potentially providing an opportunity for the diagnostic capabilities of the eTag technology to improve patient treatment and drug development.

The presentations at the ASCO meeting describe the Company's progress in addressing two critical questions related to the treatment of HER2(+) breast cancer patients. First, why don't all HER2(+) breast cancers respond equally well to targeted therapy with Herceptin. And second, why do many HER2(+) breast cancers develop resistance to Herceptin treatment. The presentations are:

'Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2-HER2 dimerization in a clinic-based cohort of patients with metastatic breast cancer.'

'HER2 expression and HER2-HER2 dimerization identifies subpopulations of metastatic breast cancer patients with different probabilities of long-term su rvival following trastuzumab treatment and with different requirements for concomitant chemotherapy'

Patterns of HER-family receptor dimerization in trastuzumab susceptible and trastuzumab resistant cell lines

'The eTag platform represents a powerful new tool for advancing personalized medicine in cancer treatment,'said Monogram CEO Bill Young. 'By providing quantitative measurements to characterize disease at the molecular level and by detecting the protein complexes to help accurately predict an individual patient's response to specific therapies, eTag technology may empower oncologists with the critical information needed to improve patients' lives and may help drive the development of more effective targeted cancer therapies.'


'"/>




Related medicine news :

1. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
2. Childrens Hospital Boston Presents at the Society for Adolescent Medicine Annual Meeting
3. IDM Pharma Presents Preliminary Results of Melanoma Vaccine Clinical Trial
4. Hormone Deficiency Results In Miscarriage
5. Breast Implants May Interfere With The Interpretation Of Mammogram Results
6. DNA Testing For More Accurate Results
7. Operating on a Beating Heart Yields Better Results For Blocked Heart Arteries
8. Intense Fight Against Polio In India Gets Results
9. Deadly Diarrhoea Vaccine – Trail Results Promising
10. Novartis MS Drug Shows Promising Results
11. Results Of Human Trials Of Hungarian Bird-Flu Vaccine Expected Today
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/9/2016)... ... February 09, 2016 , ... February is Heart Awareness Month, and to celebrate ... the month to the American Heart Association, New Mexico chapter. , A Heart Rate ... and Health Quest’s INSiGHT Pulse Wave Profiler utilizes a non-invasive technology to determine a ...
(Date:2/9/2016)... Campbell, California (PRWEB) , ... ... ... of automated print and e-book publishing software, in partnership with Snowfall4pod Digital, ... AVALANCHE – a comprehensive book publishing, content management, global distribution and print-on-demand ...
(Date:2/9/2016)... ... 2016 , ... The Journal of Pain Research has published the ... , As corresponding author Dr John F. Peppin says “Terminology matters, yet little attention ... pain patients. ‘Chronic cancer pain’ and ‘chronic non-cancer pain’ are replete in the ...
(Date:2/9/2016)... ... February 09, 2016 , ... METTLER ... ensure lab personnel have a basic understanding of the techniques they use so ... understanding will help them reduce waste and rework to create a leaner overall ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... sealing company , is proud to announce that many of their franchises have ... customer service. The hard surface restoration franchises received customer recognition through positive reviews ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... Florida , February 9, 2016 ... today announced a collaboration with 10x Genomics to ... (NGS), single-cell biology and bioinformatics. --> ... a collaboration with 10x Genomics to develop and ... biology and bioinformatics. --> QIAGEN N.V. ...
(Date:2/9/2016)... 2016 The new report "Global Diagnostic Ultrasound Devices Market ... group reveals that global diagnostic ultrasound devices market was valued at ... 7,466.3 million by 2019 at a CAGR of 6.8% from 2015 ... market has been analyzed for six geographies of North ... , Latin America , Middle-East ...
(Date:2/9/2016)... This TforG report includes the Surgical Procedures Database with ... in South Korea . To add ... written and numerical analysis on the current trends, size, ... latest reforms of the local Healthcare system are clearly ... The report helps businesses gain a unique insight into ...
Breaking Medicine Technology: